Right heart thrombus (RHT) presents a challenging clinical dilemma with potentially catastrophic mortality. An increasing number of devices and techniques for endovascular thrombectomy have been developed in the last 20 years with overlapping applications in treating pulmonary embolism (PE), deep vein thrombus (DVT), and RHT.1-4

RHT is typically associated with PE from DVT but may develop in situ in the setting of cardiac chamber dilatation or hypokinesis. Catheter-related atrial thrombus is distinct and associated with central venous catheters or electrical pacer wires.5,6 Valvular endocarditis with mass-like vegetations and catheter- or wire-related septic thrombi can also occur, leading to septic PE.7 Left untreated, RHT is associated with a high mortality risk approaching 90% to 100%. Patients with RHT present with more hemodynamic instability and have a higher risk of recurrent PE and PE-related mortality.8

Although traditional therapies for RHT include anticoagulation, thrombolysis, and surgical embolectomy, there is a dearth of evidence in the registries regarding endovascular thrombectomy given its relative novelty. Endovascular aspiration thrombectomy systems have quickly become more favorable for right heart mass removal given their ability to rapidly debulk with faster procedure times and lower morbidity than operative embolectomy and the lesser risk of major hemorrhage compared with thrombolysis.9,10 Several devices such as the FlowTriever (Inari Medical) and the AngioVac system (AngioDynamics, Inc.) have been used in the treatment of RHT.11,12 Treatment decisions are heavily influenced by patient factors, operator experience, and local resources. This case report discusses the use of the new AlphaVac F22 system (AngioDynamics, Inc.) in the removal of right atrial (RA) thrombus. The AlphaVac F22 system, which has been 510(k) cleared by the FDA, is indicated for the removal of thrombi or emboli from the venous system.

**CASE REPORT**

**Initial Presentation**

A man in his late 70s presented as an emergent intra-hospital transfer with left lower extremity DVT, suspicion for caval thrombosis, and known large-volume mobile RA thrombus and bilateral PE with an intermediate-risk presentation seen on preoperative CT (Figure 1A) and echocardiography (Figure 1E). The patient was brought to the interventional radiology (IR) suite, and right common femoral vein access was utilized for placement of a 26-F DrySeal sheath (Gore & Associates). The inferior vena cava (IVC) was catheterized using a 0.035-inch Amplatz guidewire. The initial venogram demonstrated a patent IVC, which was discordant with CT findings and later thought to represent mixing artifact. Extensive mobile clot burden was confirmed within the RA on echocardiography, without evidence of adherence to the cardiac wall. Pulmonary angiography demonstrated extensive clot burden in the right lobar pulmonary artery (PA) (Figure 1C) and segmental PE within the left.

**Procedural Overview**

Mechanical thrombectomy was performed within the RA with the 22-F AlphaVac thrombectomy cannula. Under fluoroscopic and transesophageal echocardiographic guidance, the RA was cannulated with the device (Figure 1B), and subsequently, two 30-cc aspirations with vacuum lock resulted in complete evacuation of the RA thrombus (Figure 1D). The estimated blood loss was 200 cc. Attention was then turned to the pulmonary circulation.

PA pressure measurements were obtained via a multiple side-hole catheter. Mean right main PA pressure measured
45 mm Hg and left main PA systolic pressure measured 41 mm Hg. Given the patient’s size and catheter length limitation, the AlphaVac cannula in its current iteration could not be utilized for pulmonary thrombectomy. Thus, the decision was made to perform catheter-directed lysis and place an IVC filter to prevent new PE. The patient was stable throughout the procedure and was transferred to the intensive care unit (ICU) for overnight lysis.

**Postprocedural Course**

The patient was brought to the IR suite the following day for repeat pulmonary angiography and PA pressure measurement and underwent further thrombectomy after lysis. Two weeks later, the patient was discharged to a rehabilitation facility with oral anticoagulation.

**DISCUSSION**

This case highlights the utility of the AlphaVac aspiration thrombectomy device for RA thrombus retrieval. The AlphaVac is a first-generation aspiration thrombectomy device designed with the benefits of the AngioVac system and allowing for rapid large-volume aspiration without the need for extracorporeal bypass. The system consists of an ergonomic handle that acts as the engine or the vacuum source, a 22-F cannula (20° and 180° funnel tip options), an obturator, and a waste bag assembly. There are four waste bags included, holding up to 250 cc of blood or fluid per bag. The new catheter retains its proprietary funnel tip (similar to the AngioVac system), which aids in the guidance and removal of the intravascular material. The AlphaVac handle creates an off-circuit method of action and includes the volume-limiting switch, which allows the user to dictate the amount of aspirated material per pull of the handle, thereby minimizing blood loss during the procedure. The volume-limiting switch can be set on either a 10- or 30-cc setting. Once the material is engaged, the user may choose to either remain in the 10-cc setting or switch to 30 cc to initiate aspiration. There is also a vacuum lock mechanism that enhances user control by maintaining negative pressure with single-hand operation.

The case discussed in this article clearly shows the efficacy of the AlphaVac F22 system in the removal of thrombus from the RA. However, the current iteration is not suitable for accessing the PAs. The APEX-AV trial, which is currently in its start-up phase (site recruitment), will evaluate the safety and efficacy of the new AlphaVac F18 system in acute intermediate-risk PE patients. The AlphaVac F18 thrombectomy system consists of an 18-F cannula (105-cm long) with an 85° angled tip and was recently cleared by the FDA for the removal of thrombus from the venous system. The primary efficacy endpoint of the APEX-AV study is reduction in right ventricular/left ventricular diameter ratio between baseline and 48 hours postprocedure as assessed by CTA. The primary safety endpoint is the rate of major adverse events, including device-related death and major bleeding within the first 48 hours after the index procedure. The secondary efficacy endpoints include use of thrombolytics within 48 hours of the procedure, length of stay in the ICU/hospital within 30 days postprocedure, and change in modified Miller Index between baseline and 48 hours postprocedure as assessed by CTA. The secondary safety endpoints include rate of device-related complications, including clinical deterioration, cardiac injury, pulmonary vascular injury, major bleeding, and device-related death within 48 hours of the index procedure. This study will also conduct an exploratory analysis to evaluate unmet health care needs with study enrollments and outcomes. The clinical study is to be conducted at up to 20 investigative sites within the United States, and patients will be followed for 30 days post–index procedure. Overall study duration is estimated to be 18 months.

**CONCLUSION**

This case report demonstrates the efficacy of the AlphaVac F22 system in the removal of thrombus from
the RA and shows the utility of such thrombectomy devices in preventing PE. Overall, the AlphaVac system, which has retained some of the features and benefits of the AngioVac system, presents a simplified setup (without the veno-venous circulation) for the removal of thrombi from the venous system, including the right heart. However, additional studies including prospective trials with adequate sample size are needed to validate its safety and efficacy in advancing patient care.

This case study represents the experience of one institution and is not indicative of all procedure results. Views and opinions expressed in the article are of the author and do not necessarily reflect the views and options of AngioDynamics, Inc., its affiliates or subsidiaries or their employees.


Mona Ranade, MD
Assistant Professor, Interventional Radiology
David Geffen School of Medicine at UCLA
Los Angeles, California
Disclosures: Paid consultant with AngioDynamics, Inc.; Co-Principal Investigator of the APEX trial.

John M. Moriarty, MD, FSIR, FSVM
Associate Professor of Radiology and Medicine (Cardiology)
UCLA Interventional Radiology
David Geffen School of Medicine at UCLA
Los Angeles, California
Disclosures: Consultant with AngioDynamics, Inc.